Figure 1 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood

Data basic properties and analysis overview. A, Distribution, annotation, and cell fractions of 12 major immune cell types in matched tumor-PBMC CD45⁺ scRNA-seq data from 26 patients with treatment-naïve HNSCC. B, A volcano plot showing differential fractions of abundance of 12 major immune cell types between tumor tissues and PBMCs. C, Significantly differentially expressed genes in 12 annotated immune cell types from tumor tissues and PBMCs. D, An overview of the study: First, (1) the ICFs and (2) the gene expression levels of major immune cell types in the TME are predicted from the blood scRNA-seq data. Then, (3) immune signatures are identified from immune information in the blood and in the TME (which is predicted from the blood) to predict patients’ ICB response. FPR, false-positive rate; TPR, true-positive rate.